At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02595 GENFLEET-B
Closed The day following Ching Ming Festival 04-02 16:08:21
36.500
-0.480
-1.30%
High37.860Low35.040Vol1.68M
Open37.860D1 Closing36.980Amplitude7.63%
Mkt Cap13.51BTradable Cap12.34BTotal Shares370.00M
T/O60.63MT/O Rate0.50%Tradable Shares338.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 46.6%
Simply Wall St.  ·  06:04
3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 46.6%
Wellington Management Increases Stake in GENFLEET-B by Approximately 318,247 Shares at Average Price of HK$30.88
Stock News  ·  03-30
Wellington Management Increases Stake in GENFLEET-B by Approximately 318,247 Shares at Average Price of HK$30.88
GenFleet Therapeutics SEHK 2595 Deepens Losses As Revenue Growth Tests Bullish Narratives
Simply Wall St.  ·  03-27
GenFleet Therapeutics SEHK 2595 Deepens Losses As Revenue Growth Tests Bullish Narratives
CLSA Raises Target Price for GENFLEET-B to HK$61.9, Keeps Outperform Rating
Stock News  ·  03-26
CLSA Raises Target Price for GENFLEET-B to HK$61.9, Keeps Outperform Rating
Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List
Stock Track  ·  03-25
Stock Track | GENFLEET-B Soars 5.34% Intraday as Key Drug Added to China's National Reimbursement List
BRIEF-Genfleet Therapeutics (Shanghai) Posts FY Loss RMB1.79 BLN
Reuters  ·  03-25
BRIEF-Genfleet Therapeutics (Shanghai) Posts FY Loss RMB1.79 BLN
GENFLEET-B Announces Appointment of Huang Meifeng as Co-Company Secretary
Stock News  ·  03-25
GENFLEET-B Announces Appointment of Huang Meifeng as Co-Company Secretary
GENFLEET-B Reports Annual Loss Widening to 17.95 Billion Yuan
Stock News  ·  03-25
GENFLEET-B Reports Annual Loss Widening to 17.95 Billion Yuan
GenFleet Therapeutics FY 2025: Revenue Climbs 24% While Fair-Value Charges Deepen Net Loss; Cash Reserves Surpass RMB 2.07 Billion
Bulletin Express  ·  03-25
GenFleet Therapeutics FY 2025: Revenue Climbs 24% While Fair-Value Charges Deepen Net Loss; Cash Reserves Surpass RMB 2.07 Billion
GenFleet Therapeutics Updates Audit Committee Charter to Strengthen Governance Framework
Bulletin Express  ·  03-25
GenFleet Therapeutics Updates Audit Committee Charter to Strengthen Governance Framework
Genfleet Therapeutics (Shanghai) Inc - FY Loss RMB1.79 Bln
THOMSON REUTERS  ·  03-25
Genfleet Therapeutics (Shanghai) Inc - FY Loss RMB1.79 Bln
GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million
Reuters  ·  03-25
GenFleet FY2025 net loss widens to RMB 1.79 billion as revenue rises 24.41% to RMB 130 million
Genfleet KRAS G12C inhibitor fulzerasib added to China’s national drug reimbursement list
Reuters  ·  03-25
Genfleet KRAS G12C inhibitor fulzerasib added to China’s national drug reimbursement list
Wellington Management Increases Stake in GENFLEET-B by 3.82 Million Shares at HK$25.5 Each
Stock News  ·  03-23
Wellington Management Increases Stake in GENFLEET-B by 3.82 Million Shares at HK$25.5 Each
GENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting
Stock News  ·  03-20
GENFLEET-B (02595) to Present Preclinical Data for Three RAS Pathway Targeted Therapies at 2026 AACR Annual Meeting
GenFleet Therapeutics to present preclinical RAS-pathway data at AACR annual meeting
Reuters  ·  03-20
GenFleet Therapeutics to present preclinical RAS-pathway data at AACR annual meeting
Wellington Management Group LLP Increases Stake in GENFLEET-B by 2.524 Million Shares
Stock News  ·  03-19
Wellington Management Group LLP Increases Stake in GENFLEET-B by 2.524 Million Shares
GENFLEET-B (02595) Schedules 24 Mar 2026 Board Meeting to Approve FY2025 Results and Final Dividend Proposal
Bulletin Express  ·  03-12
GENFLEET-B (02595) Schedules 24 Mar 2026 Board Meeting to Approve FY2025 Results and Final Dividend Proposal
GenFleet Therapeutics to hold board meeting to approve annual results and consider final dividend
Reuters  ·  03-12
GenFleet Therapeutics to hold board meeting to approve annual results and consider final dividend
GENFLEET-B Shares Surge Over 11% on Inclusion in Southbound Trading and Anticipated GFH375 Data Release
Stock News  ·  03-09
GENFLEET-B Shares Surge Over 11% on Inclusion in Southbound Trading and Anticipated GFH375 Data Release
No data available

Introduction

Company Name.
GENFLEET-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
GenFleet Therapeutics (Shanghai) Inc is a China-based company principally engaged in the development of innovative drugs. The Company provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The Company is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The Company mainly primarily operates in the domestic and international markets.
Issue price:
--